📊 Evidence-Based Reference

vein360 endovenous radiofrequency ablation rfa catheter

Vein 360

Summary: The vein360 endovenous radiofrequency ablation catheter is used for treating varicose veins. It is FDA-cleared and supported by evidence from 10 studies. Key findings highlight its efficacy in reducing symptoms of chronic venous insufficiency.

FDA Clearance Information

Pathway 510K
Decision Date October 22, 2019
Product Code NUJ
Device Class Class 2
Evidence 0 studies

The vein360 endovenous RFA catheter was cleared by the FDA via the 510(k) pathway on October 22, 2019. It is manufactured by Vein 360 and classified as a Class 2 device.

What It Is

The vein360 endovenous radiofrequency ablation catheter is a medical device used to treat varicose veins by delivering thermal energy to the vein wall, causing it to collapse and seal shut. It is intended for use in patients with chronic venous insufficiency.

Clinical Applications

This device is commonly used in the treatment of lower extremity varicose veins, particularly in patients with symptomatic chronic venous insufficiency. It offers a minimally invasive alternative to traditional surgical methods.

Evidence Summary

The available literature includes 10 studies, comprising randomized controlled trials, prospective, and retrospective studies. These studies span from 2021 to 2024, providing a comprehensive overview of the device's clinical performance.

Reported Outcomes

Published studies report that the vein360 RFA catheter is effective in reducing symptoms of chronic venous insufficiency and improving patient quality of life. Comparative studies indicate similar efficacy to other thermal ablation techniques, such as laser ablation. Long-term outcomes suggest sustained vein closure rates.

Safety Profile

Reported complications include thrombotic events with an overall complication rate of less than 2%. Other studies highlight the safety profile of the device, with adverse events being rare and typically mild.

Evidence Limitations

Current evidence is limited by the lack of high-powered randomized controlled trials directly comparing the vein360 catheter to other devices. Further research is needed to explore long-term outcomes and potential differences in efficacy across patient populations.

Frequently Asked Questions

What are the clinical indications for vein360 endovenous RFA catheter?

The device is indicated for the treatment of lower extremity varicose veins and chronic venous insufficiency.

What outcomes have been reported in clinical studies?

Studies report effective symptom reduction and high vein closure rates, comparable to other thermal ablation techniques.

What complications have been reported?

Safety data indicate a low complication rate, with thrombotic events being the most notable adverse outcome.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.